←
Brown Pathology and Laboratory Medicine506 posts
Brown Pathology and Laboratory Medicine avatar✓

Brown Pathology and Laboratory Medicine ✓

@BrownPathology

A dynamic hub of interdisciplinary research, clinical practice, and commitment to medical education. Meet our Residents & Fellows: @BrownPathRes

◷ Joined November 2020▧ 103 Photos and videos
Brown University avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
Brown University@BrownUniversity·Oct 16

New research could pave the way for treatments that prevent neurodegenerative diseases before they begin. As part of a multi-institution research project, Brown University professor Nicolas Fawzi and his team will study proteins at the atomic level to help researchers better understand how protein dysfunction contributes to diseases such as Alzheimer's and Parkinson's. buff.ly/khxN5YN

Kamran Mirza MD PhD - کامران مرزا avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
Kamran Mirza MD PhD - کامران مرزا@KMirza·Oct 17

Plasma cells are amazing! Their appearance reflects an extraordinary commitment to antibody production: the eccentric nucleus, the abundant cytoplasm filled with rough endoplasmic reticulum, the pale Golgi hof. Features we learn early in training become more interesting as we come to understand what they represent. Some plasma cells persist for decades, producing antibodies against infections we have long forgotten. I find that remarkable. Part of our immunologic history is maintained by these cells, quietly at work in the marrow. In neoplasia, they may retain that familiar appearance while producing a protein capable of causing profound injury. A seemingly mature plasma cell can belong to a clone whose antibodies damage the kidneys, deposit in tissues, or increase blood viscosity. Its appearance alone tells us surprisingly little about the harm it can cause. (Images of plasma cell myeloma and rouleaux) #Hematopathology #Pathology #hemepath #mmsm

Post attachmentPost attachmentPost attachment
Janira Navarro avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
Janira Navarro@Janiranavarro·Oct 11

Flat Epithelial Atypia (FEA), left pic Focal Atypical Ductal Hyperplasia (ADH), right pic Dr. Allison. 2026 Diagnostic Pathology Update #USCAP #pathology #PathX

Post attachment
Janira Navarro avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
Janira Navarro@Janiranavarro·Sep 23

Gleason Pattern 4: Poorly formed glands None of these glands have lumina, this is not tangential section . Probably you could think this is grade 5. Do not call it grade 5 Across all clinical outcome groups, this morphologic pattern is NOT associated with metastatic potential. Dr. McKenney Prostatic Adenocarcinoma Grading: 2026 Update #USCAP #pathX #pathology

Post attachmentPost attachment
International Society of Urological Pathology avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
International Society of Urological Pathology@IntSocUropath·Sep 27

Join us at the ISUP–IAP Companion Meeting: Recent Advances in Urologic Surgical Pathology! #IAP2026 🇯🇵 🗓 Sunday, Oct 11, 2026
⏰ 3:30–5:30 PM
📍 Palace Room (Room 9, 2nd Floor), Fukuoka International Congress Center, Fukuoka, Japan

Post attachment
Liang Cheng, MD avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
Liang Cheng, MD@LiangChengMD·Sep 19

The ISUP Stockholm meeting was a tremendous success - an unforgettable gathering and an inspiring milestone for the future of precision pathology and management of GU malignancies. On September 12, 2026, 112 experts and colleagues from around the world came together at the Grand Hôtel Stockholm for a multidisciplinary expert consultation on precision biomarker testing in bladder and prostate cancer. We are living through one of the most transformative periods in the history of pathology. Cancer diagnosis is no longer defined by morphology alone. Increasingly, diagnosis, classification, prognosis, therapeutic selection, and disease monitoring are being shaped by biomarkers, molecular testing, and artificial intelligence.Our Stockholm conference embraced this transformation. Together, we examined the current and future landscape of biomarker testing in bladder and prostate cancer, including standardization of testing and reporting, specimen selection, liquid biopsy, artificial intelligence, digital pathology, and the critical unanswered questions that will shape the next generation of research and clinical practice. This meeting was not the conclusion of a process -it was the beginning of one. The conversations will continue. The evidence will evolve. Our recommendations will be refined, challenged, and strengthened. New technologies will emerge, new biomarkers will enter clinical practice, and new questions will undoubtedly arise. What will remain constant is our shared commitment to advancing science, improving standards, and ultimately providing better care for our patients. I am deeply grateful to our outstanding Working Group Chairs - Michelle Downes, Antonio Lopez-Beltran, Gladell Paner @GladellPaner , and Alessia Cimadamore, my co-Chair, Arno van Leenders - and to every member of our Working Groups for their extraordinary expertise, dedication, preparation, and countless contributions. My sincere thanks also go to every attendee who traveled to Stockholm and contributed ideas, questions, debate, and perspective. A very special thank to Katrina Collins, @katcollmd Nancy Greenland, and Alessia Cimadamore @AlessiaCim , who devoted countless hours to organizing the meeting and managing the many logistical details behind the scenes. @IntSocUropath

Post attachmentPost attachmentPost attachmentPost attachment
Ankur Sangoi avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
Ankur Sangoi@slusagar·14 May 2024

#GUpath: nested pattern invasive urothelial carcinoma? 😨 NOPE! just normal VonBrunn nests in the upper urothelial tract of this kidney😅

Post attachmentPost attachmentPost attachmentPost attachment
Janira Navarro avatar
⟳ Brown Pathology and Laboratory Medicine retweeted
Janira Navarro@Janiranavarro·Sep 14

WHAT'S NEW IN NEUROENDOCRINE TUMORS (WHO 6TH EDITION 2026) Presence of any nuclear labeling with Ki67 above background is considered positive Ki67 stain is not a positive or negative stain. It is dynamically expressed throughout the cell cycle Stronger Ki67 IHC assays tend to flatten this variation Dr. Bellizzi GIPS pathcast youtube.com/live/o8IqIDiN_Jw… #pathology #PathX

Post attachmentPost attachment